The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Quviviq



Idorsia Pharmaceuticals Deutschland GmbHEU/1/22/1638/003-004

Main Information

Trade NameQuviviq
Active SubstancesDaridorexant hydrochloride
Dosage FormFilm-coated tablet
Licence HolderIdorsia Pharmaceuticals Deutschland GmbH
Licence NumberEU/1/22/1638/003-004

Group Information

ATC CodeN05 PSYCHOLEPTICS

Status

License statusAuthorised
Licence Issued29/04/2022
Legal status*** AWAITING VALUE ***
Supply Status
Advertising Status*** AWAITING VALUE ***
Conditions of Licence
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back